Source strength determination in iridium-192 and cobalt-60 brachytherapy: A European survey on the level of agreement between clinical measurements and manufacturer certificates

• Main Authors: Javier Vijande, Åsa Carlsson Tedgren, Facundo Ballester, Dimos Baltas, Panagiotis Papagiannis, Mark J. Rivard, Frank-André Siebert, Larry De Werd, Jose Perez-Calatayud
• Format: Article
• Language: English
• Published: Elsevier 2021-07-01
• Series: Physics and Imaging in Radiation Oncology
• Subjects: RAKR; Calibration; HDR; PDR; Brachytherapy
• Online Access: http://www.sciencedirect.com/science/article/pii/S2405631621000427

Background and purpose: Brachytherapy treatment outcomes depend on the accuracy of the delivered dose distribution, which is proportional to the reference air-kerma rate (RAKR). Current societal recommendations require the medical physicist to compare the measured RAKR values to the manufacturer source calibration certificate. The purpose of this work was to report agreement observed in current clinical practice in the European Union. Materials and methods: A European survey was performed for high- and pulsed-dose-rate (HDR and PDR) high-energy sources (192Ir and 60Co), to quantify observed RAKR differences. Medical physicists at eighteen hospitals from eight European countries were contacted, providing 1,032 data points from 2001 to 2020. Results: Over the survey period, 77% of the 192Ir measurements used a well chamber instead of the older Krieger phantom method. Mean differences with the manufacturer calibration certificate were 0.01% ± 1.15% for 192Ir and –0.1% ± 1.3% for 60Co. Over 95% of RAKR measurements in the clinic were within 3% of the manufacturer calibration certificate. Conclusions: This study showed that the agreement level was generally better than that reflected in prior societal recommendations positing 5%. Future recommendations on high-energy HDR and PDR source calibrations in the clinic may consider tightened agreements levels.